Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05411094
Title	Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	pancreatic cancer
Therapies	Durvalumab + Olaparib
Age Groups:	adult \| senior
Covered Countries	USA \| CAN

Facility	Status	City	State	Zip	Country	Details
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	RECRUITING	Irvine	California	92612	United States	Details
Los Angeles General Medical Center	RECRUITING	Los Angeles	California	90033	United States	Details
USC / Norris Comprehensive Cancer Center	RECRUITING	Los Angeles	California	90033	United States	Details
UC Irvine Health/Chao Family Comprehensive Cancer Center	RECRUITING	Orange	California	92868	United States	Details
University of Michigan Comprehensive Cancer Center	RECRUITING	Ann Arbor	Michigan	48109	United States	Details
University of Michigan - Brighton Center for Specialty Care	SUSPENDED	Brighton	Michigan	48116	United States	Details
UNC Lineberger Comprehensive Cancer Center	RECRUITING	Chapel Hill	North Carolina	27599	United States	Details
Ohio State University Comprehensive Cancer Center	RECRUITING	Columbus	Ohio	43210	United States	Details
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	RECRUITING	Madison	Wisconsin	53718	United States	Details
University of Wisconsin Carbone Cancer Center - University Hospital	RECRUITING	Madison	Wisconsin	53792	United States	Details
University Health Network-Princess Margaret Hospital	RECRUITING	Toronto	Ontario	M5G 2M9	Canada	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field